MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) has announced impressive financial results for the third quarter of 2024, achieving a record revenue of $19.0 million. This marks a robust 26% increase over the same period last year, underscoring the rising demand for the company’s OviTex® and OviTex PRS Reinforced Tissue Matrix products. Unit sales for these products saw year-over-year growth of 39% and 44%, respectively.
The surge in revenue is attributed to the addition of new customers and a boost in international sales. However, the increase in smaller-sized product sales, including those compatible with robotic procedures, led to a decline in average selling prices, slightly impacting the revenue mix.
In a strategic move to bolster financial health, TELA Bio recently closed an underwritten public offering, yielding gross proceeds of approximately $46.0 million. This infusion of funds is expected to support the company’s path to profitability, as they aim to reduce operating expenses in 2025 by $5.0 million to $10.0 million.
Despite challenges such as IV fluid shortages due to natural disasters, TELA Bio reiterated its full-year revenue guidance for 2024, anticipating between $74.5 million and $76.5 million, reflecting a 27% to 31% increase from 2023.
In terms of profitability, TELA Bio reported a net loss of $10.4 million for the third quarter of 2024, an improvement from the $11.0 million loss in the same quarter last year. The company’s cash and cash equivalents stood at $17.3 million as of September 30, 2024.
Antony Koblish, President and CEO of TELA Bio, expressed confidence in the company’s growth strategy, emphasizing the focus on expanding market share in high-volume minimally invasive and robotic procedures. With the recent financial boost and strategic cost reductions, TELA Bio is well-positioned to drive future growth and achieve its financial goals.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.